GLP1R and familial pancreatic carcinoma: Concerns were raised following several publications that identified an increased risk for pancreatitis and pancreatic cancer in patients taking GLP-1 receptor agonists (GLP-1RA).1,2 A Food and Drug Administration (FDA) warning on pancreatic safety followed,3 urging both patients and health care professionals to report adverse events involving incretin mimetics to the FDA MedWatch program.